Suven Pharma reported a 78% YoY rise in Q3FY25 net profit to Rs 83.3 crore, with revenue growing 40% to Rs 307.2 crore, ...

Suven Pharma, backed by Advent, reported a 78% year-on-year rise in net profit to Rs 83.3 crore for Q3FY25 driven by strong ...

HYDERABAD: When 53-year-old Lavanya (name changed) was diagnosed with breast cancer in 2024, the news brought shock, fear and ...

One of the well-known pharmaceutical businesses, Sigachi Industries Limited (NSE: SIGACHI), has announced the inauguration of ...

Discover the importance of antibiotics, bacterial cell walls, and resistance mechanisms in fighting bacterial infections effectively.

Gland Pharma reported a 6.7% year-on-year (YoY) growth in net profit for Q3 FY25, at ₹204.7 crore, compared to ₹191.9 crore ...

HYDERABAD: When 53-year-old Lavanya (name changed ... the high cost of medications remains a concern because essential components and molecules are imported. Local production of these molecules ...

The EBITDA margin stood at 26% in the reporting quarter versus 23.1% YoY. The results came after the close of the market ...

Gland Pharma's consolidated net profit increased 6.67% to Rs 204.70 crore despite 10.42% decline in revenue from operations to Rs 1,384.1 crore in Q3 FY25 over Q3 FY25.

Despite a dip in base business revenue, Gland Pharma Ltd (NSE:GLAND) reports robust margin improvements and strategic growth initiatives.